Nootropic Peptides
Explore cognition and neuroprotection research with human, animal and laboratory findings kept distinct, including study-integrity and product-identity questions.
Category Overview
This category groups compounds studied for cognition, anxiety, neuroprotection and recovery after neurological disease. Proposed mechanisms include growth-factor signaling, neuronal stress responses and neurotransmitter-related pathways. A laboratory endpoint does not establish improved everyday cognition.
Evidence differs substantially among products: cell/mouse experiments, small human symptom studies and named-country product information should be read separately. This set does not establish a class-wide advantage in cognitive durability, tolerance or safety.
Semax and Selank have small human studies and named Russian nasal-product information. Those sources are not US approval or proof of universal cognitive enhancement. Dihexa requires an additional integrity check: its 2014 mechanism paper was retracted in 2025, while the 2013 development paper has a notice of concern. Other positive and negative animal findings are retained in its profile.
For compounds without a dossier profile, the PE-22-28 original study used cells and mice, and the P021 original study used a transgenic mouse model. Chemical identity and model must travel with those promising results.
All Nootropic Peptides
Small operator and post-stroke rehabilitation findings differ from laboratory and imaging endpoints. FDA’s 2026 assessment states free base and acetate are not approved-drug components; its review has language-access limits. Russian product information is separate.
Small human studies report anxiety and adjunct-treatment findings; imaging and animal endpoints remain separate. Named Russian nasal-drop information does not establish US product approval or a universal regimen.
Mixed animal findings: the 2014 mechanism paper was retracted in 2025, and the 2013 development paper has a 2021 notice of concern. The reviewed sources do not establish a human cognitive treatment or dose.
Seven-residue shortened spadin analog studied in TREK-1 cell experiments and mouse behavioral models, with promising preclinical findings. Distinct from 17-residue parent spadin; these are not human antidepressant or cognitive-efficacy results.
Limited human reports and a rectal-trial account do not establish a general treatment effect. FDA states the assessed free-base and acetate forms are not components of approved drugs; pending policy review is separate.
Human mixture studies include positive rehabilitation and TBI findings, neutral acute-stroke outcomes and safety qualifications. Austrian product information should not be treated as US approval.
P021 is a CNTF-derived modified peptide studied in transgenic mice, with positive synaptic and cognitive findings after dietary administration. It is not an isolated active fragment of the porcine Cerebrolysin mixture; commercial P21 identity needs confirmation.
Cell and animal treatment findings are distinct from human biomarker comparisons. HNG improved selected metabolic measures without significantly extending female mouse lifespan. These sources do not establish a human treatment regimen.
Disclaimer: Most nootropic peptides are not FDA-approved in the United States. Cognitive enhancement claims are based on limited research. This information is for educational purposes only. Do not self-medicate with research peptides for cognitive enhancement.